Pharma Phriday (March 27, 2026): Advances in obesity, diabetes, and rare neuromuscular disease; new approvals in lymphoma, paediatrics, ophthalmology, and obesity; major acquisitions in haematology and autoimmune; and licensing deals for T-cell engagers, oncology, subQ delivery, and AI.

This week we've had Eyes On BioPharma updates and US Regulatory moves on EU Tariffs. Check out Lilly 's data and expectations for Verzenio, GSK's deal with Hengrui, Novo Nordisk & Replicate Therapeutics agreement on sRNA, and the latest on US-EU Pharma tariffs.